CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), taking place in Anaheim, CA from November 9-13. The presentations are:
- Understanding Why Hereditary Angioedema Patients Often Do Not Carry Their On-Demand Treatment with Them - #P078: Bob Geng, Sally van Kooten, Markus Heckmann, Sherry Danese, Ledia Goga, Cristine Radojicic. Results shared as an oral poster presentation and Q&A on Friday, November 10 from 4:30 - 4:45 pm PT at Monitor 13
- Treatment of Hereditary Angioedema (HAE) with Normal C1-INH (HAE-nC1-INH) –A Real-World ACARE Survey - #P059: Marcus Maurer, Markus Magerl, Marc A. Riedl, Sherry Danese, Julie Ulloa, Vibha Desai, Paul K. Audhya. Results shared as an oral poster presentation and Q&A on Friday, November 10 from 5:15 - 5:30 pm PT at Monitor 12
- Treatment Patterns Among Individuals with Hereditary Angioedema in the United States - #P085: Raffi Tachdjian, Rose Chang, Maral DerSarkissian, Kristen A. Cribbs, Betsy J. Lahue, Shawn Czado, Vibha Desai. Results shared as an oral poster presentation and Q&A on Saturday, November 11 from 11:50 am - 12:05 pm PT at Monitor 13
- Diagnosing Hereditary Angioedema (HAE) with Normal C1-INH (HAE-nC1-INH) –A Real World ACARE Survey - #P069: Marc A. Riedl, Markus Magerl, Marcus Maurer, Sherry Danese, Julie Ulloa, Vibha Desai, Paul K. Audhya. Results shared as an oral poster presentation and Q&A on Sunday, November 12 from 12:05 - 12:20 pm PT at Monitor 12
- Refining Prevalence Estimates of Hereditary Angioedema (HAE) with Normal C1-INH (HAE-nC1-INH) - #P070: Markus Magerl, Marc A. Riedl, Marcus Maurer, Sherry Danese, Julie Ulloa, Vibha Desai, Paul K. Audhya. Results shared as an oral poster presentation and Q&A on Sunday, November 12 from 12:20 - 12:35 pm PT at Monitor 12
- Anxiety Associated with On-Demand Treatment of HAE Attacks May Result in Suboptimal Attack Management - #P092: Michael Manning, Sally van Kooten, Markus Heckmann, Sherry Danese, Ledia Goga, Princess U. Ogbogu. Results shared as an oral poster presentation and Q&A on Sunday, November 12 from 12:20 - 12:35 pm PT at Monitor 13
All poster presentations will take place in the ePoster Section of the Exhibit Hall.
Links to all posters and presentations can be found on the KalVista website under “Publications”.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved target enrollment for the phase 3 KONFIDENT clinical trial. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE and other diseases.
For more information about KalVista, please visit www.kalvista.com.
For more information on the sebetralstat HAE on-demand Phase 3 KONFIDENT study, please visit www.konfidentstudy.com.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 3 KONFIDENT trial, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2023, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
